Cingulate (CING) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Cingulate (NASDAQ: CING) recently:

• 5/26/2026 – Cingulate had its “buy” rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
• 5/22/2026 – Cingulate was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/19/2026 – Cingulate had its “buy” rating reaffirmed by Roth Mkm. They now have a $10.00 price target on the stock.
• 5/16/2026 – Cingulate was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 4/20/2026 – Cingulate had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 4/8/2026 – Cingulate had its price target lowered by Ascendiant Capital Markets from $58.00 to $55.00. They now have a “buy” rating on the stock.

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.